NO20045089L - Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser - Google Patents

Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser

Info

Publication number
NO20045089L
NO20045089L NO20045089A NO20045089A NO20045089L NO 20045089 L NO20045089 L NO 20045089L NO 20045089 A NO20045089 A NO 20045089A NO 20045089 A NO20045089 A NO 20045089A NO 20045089 L NO20045089 L NO 20045089L
Authority
NO
Norway
Prior art keywords
disorders
myopia
schizophrenia
treatment
affective
Prior art date
Application number
NO20045089A
Other languages
English (en)
Norwegian (no)
Inventor
Alyson Fox
Hans O Kalkman
Yves Auberson
Kurt Lingenhohl
Hans Ch Neijt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209886A external-priority patent/GB0209886D0/en
Priority claimed from GB0209887A external-priority patent/GB0209887D0/en
Priority claimed from GB0209889A external-priority patent/GB0209889D0/en
Priority claimed from GB0210371A external-priority patent/GB0210371D0/en
Priority claimed from GB0212760A external-priority patent/GB0212760D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20045089L publication Critical patent/NO20045089L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20045089A 2002-04-30 2004-11-23 Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser NO20045089L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0209886A GB0209886D0 (en) 2002-04-30 2002-04-30 Organic compounds
GB0209887A GB0209887D0 (en) 2002-04-30 2002-04-30 Organic compounds
GB0209889A GB0209889D0 (en) 2002-04-30 2002-04-30 Organic compounds
GB0210371A GB0210371D0 (en) 2002-05-07 2002-05-07 Organic compounds
GB0212760A GB0212760D0 (en) 2002-05-31 2002-05-31 Organic compounds
PCT/EP2003/004466 WO2003092701A2 (en) 2002-04-30 2003-04-29 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders

Publications (1)

Publication Number Publication Date
NO20045089L true NO20045089L (no) 2004-11-23

Family

ID=29408096

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045089A NO20045089L (no) 2002-04-30 2004-11-23 Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser

Country Status (13)

Country Link
US (1) US20060293282A1 (pl)
EP (1) EP1501518A2 (pl)
JP (2) JP2005527600A (pl)
KR (1) KR20040101573A (pl)
CN (1) CN1649599A (pl)
BR (1) BR0309611A (pl)
CA (1) CA2482524A1 (pl)
IL (1) IL164779A0 (pl)
MX (1) MXPA04010816A (pl)
NO (1) NO20045089L (pl)
PL (1) PL371427A1 (pl)
TW (1) TW200403066A (pl)
WO (1) WO2003092701A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0310868D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
GB0324542D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
GB0324541D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
GB0325172D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
ITMI20071492A1 (it) 2007-07-24 2009-01-25 S I I T Srl Servizio Internazi "composizioni per il trattamento e la prevenzione di condizioni di vertigine e acufeni comprendenti citicolina, estratto di ginkgo biloba e flavoni dimerici di ginkgo biloba"

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
WO1996028445A1 (en) * 1995-03-14 1996-09-19 Warner-Lambert Company Novel glutamate (ampa/kainate) receptor antagonists: n-substituted fused azacycloalkylquinoxalinediones
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9604400D0 (en) * 1996-03-01 1996-05-01 Pfizer Ltd Compounds useful in therapy
AU3133697A (en) * 1996-06-05 1998-01-05 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
CA2269807C (en) * 1996-10-24 2007-04-10 Novartis Ag Substituted aminoalkanephosphonic acids
SE508138C2 (sv) * 1996-12-20 1998-08-31 Ericsson Telefon Ab L M Metod och anordning för anslutning av elektrisk komponent till kretskort
GB9802225D0 (en) * 1998-02-02 1998-04-01 Cerebrus Ltd Chemical compounds
US6291479B1 (en) * 1998-12-03 2001-09-18 Alcon Manufacturing, Ltd. Use of NR2B-selective NMDA-receptor antagonists for the treatment of ophthalmic diseases
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.

Also Published As

Publication number Publication date
JP2009137995A (ja) 2009-06-25
WO2003092701A3 (en) 2004-04-08
CN1649599A (zh) 2005-08-03
AU2003232224A1 (en) 2003-11-17
CA2482524A1 (en) 2003-11-13
PL371427A1 (pl) 2005-06-13
TW200403066A (en) 2004-03-01
KR20040101573A (ko) 2004-12-02
WO2003092701A2 (en) 2003-11-13
MXPA04010816A (es) 2005-03-07
US20060293282A1 (en) 2006-12-28
JP2005527600A (ja) 2005-09-15
IL164779A0 (en) 2005-12-18
EP1501518A2 (en) 2005-02-02
BR0309611A (pt) 2005-02-09

Similar Documents

Publication Publication Date Title
DE50214206D1 (de) Kombinationstherapie substituierter oxazolidinone
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
DE60135732D1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
ATE254461T1 (de) Behandlung von augenschmerzen
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE311226T1 (de) Die glycin-betain für seine antithrombotische verwendung
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
WO2003092701A3 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application